Isolation of Biologically Active Extracellular Vesicles-Associated AAVs for Gene Delivery to the Brain by Size Exclusion Chromatography
Carina HenriquesiD, Miguel Monteiro LopesiD, Patrícia Maia Correia de AlbuquerqueiD, David Rufino‐RamosiD, Laetitia S. GaspariD, Diana Duarte LoboiD, Kevin LeandroiD, Ana Carolina da SilvaiD, Rafael Baganha, Sónia DuarteiD, Casey A. MaguireiD, Magda M. SantanaiD, Luís Pereira de AlmeidaiD, Rui Jorge NobreiD
Abstract
Extracellular vesicles-associated adeno-associated viral vectors (EV-AAVs) emerged as a new opportunity for non-invasive gene therapy targeting the central nervous system (CNS). However, in previous reports, only AAV serotypes with known ability to cross the blood-brain barrier (BBB) have been used for EV-AAV production and testing through non-invasive strategies. In this work, we aimed at optimizing a size exclusion chromatography (SEC) protocol for the production and isolation of natural and biologically active brain-targeting EV-AAVs, that could be applied to any AAV serotype and further used for non-invasive gene delivery to the CNS. We performed a comparison between SEC and differential ultracentrifugation (UC) isolation protocols in terms of yield, contaminants, and transgene expression efficiency. We found that SEC allows a higher recovery of EV-AAVs, free of cell contaminating proteins and with less solo AAVs than UC. Remarkably, SEC-purified EV-AAVs also showed to be more potent at transgene expression than solo AAVs in neuronal cell lines. EV-AAVs exhibited the ability to cross the BBB in neonatal mice upon intravenous administration. In conclusion, SEC-purified brain-targeting EV-AAVs show to be a promising gene delivery vector for therapy of brain disorders. Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=200 SRC="FIGDIR/small/542901v1_ufig1.gif" ALT="Figure 1"> View larger version (70K): org.highwire.dtl.DTLVardef@7016b8org.highwire.dtl.DTLVardef@e3a5f3org.highwire.dtl.DTLVardef@1a43286org.highwire.dtl.DTLVardef@f110c5_HPS_FORMAT_FIGEXP M_FIG C_FIG During the production of AAV vectors, a small percentage of AAVs is secreted in association with extracellular vesicles, named "EV-AAVs". EV-AAVs can be efficiently isolated by size exclusion chromatography (SEC). When intravenously injected in mice, brain targeting EV-AAVs can cross the blood brain barrier (BBB) and transduce neuronal cells.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 1
- Organism
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- A Rapid Method for Producing Adeno-Associated Viral Vectors Suitable for Transducing Rodent Neurons in vitro and in vivo
Doug B. Howard, Reinis Svarcbahs, … Christopher T. Richie·bioRxiv·May 6, 2024
- Adeno-Associated Virus Co-Precipitation with Extracellular Vesicles for Genome Editing in Rodent Embryo
Petr Nickl, Maria Barbiera, … Radislav Sedlacek·bioRxiv·May 10, 2026
- Comparative Study of BBB-Targeting AAV Capsids on CentralNervous System Delivery Efficiency
Junhao Zhao, Xiangyu Ge, … Lei Jin·bioRxiv·Jan 21, 2026
- Broad gene expression throughout the mouse and marmoset brain after intravenous delivery of engineered AAV capsids
N. C. Flytzanis, N. Goeden, … V. Gradinaru·bioRxiv·Jun 16, 2020
- AAVs Targeting Human Carbonic Anhydrase IV Enhance Gene Delivery to the Brain
Changfan Lin, Xinhong Chen, … Viviana Gradinaru·Cell ReportsPeer-reviewed·Oct 31, 2025
- Selection of rAAV Vectors that Cross the Human Blood-Brain Barrier 1 and Target the Central Nervous System Using a Transwell Model
Ren Song, Katja Pekrun, … Mark A. Kay·Molecular Therapy — Methods & Clinical DevelopmentPeer-reviewed·Sep 7, 2022